{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:46:56Z","timestamp":1792320416191,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2002,3,1]],"date-time":"2002-03-01T00:00:00Z","timestamp":1014940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2002,3]]},"DOI":"10.1016\/s0002-9149(02)02231-2","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T01:18:58Z","timestamp":1034299138000},"page":"3-9","source":"Crossref","is-referenced-by-count":71,"special_numbering":"S1","title":["An evidence-based evaluation of the gastrointestinal safety of coxibs"],"prefix":"10.1016","volume":"89","author":[{"given":"Claire","family":"Bombardier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0002-9149(02)02231-2_BIB1","doi-asserted-by":"crossref","first-page":"22903","DOI":"10.1074\/jbc.274.33.22903","article-title":"Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition","volume":"274","author":"Marnett","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB2","first-page":"F181","article-title":"Prostanoid biosynthesis and mechanisms of action","volume":"263","author":"Smith","year":"1992","journal-title":"Am J Physiol"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI200113455","article-title":"Genetic and pharmacological analysis of prostanoid receptor function","volume":"108","author":"Narumiya","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(98)12154-2","article-title":"COX-2 inhibitors","volume":"353","author":"Hawkey","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1146\/annurev.pharmtox.38.1.97","article-title":"Cyclooxygenases 1 and 2","volume":"38","author":"Vane","year":"1998","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1006\/bbrc.1993.1062","article-title":"Characterization of the promoter of human prostaglandin H synthase-1 gene","volume":"190","author":"Wang","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB7","first-page":"156","article-title":"Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues","volume":"330","author":"O\u2019Neill","year":"1993","journal-title":"FEBS Lett"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB8","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1155\/S0962935196000452","article-title":"Cyclooxygenase-2 and its regulation in inflammation","volume":"5","author":"Bakhle","year":"1996","journal-title":"Mediators Inflamm"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB9","doi-asserted-by":"crossref","first-page":"12013","DOI":"10.1073\/pnas.91.25.12013","article-title":"Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain","volume":"91","author":"Seibert","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/rheumatology\/37.7.773","article-title":"Detection of COX-1 and COX-2 isoforms in synovial fluid cells from inflammatory joint diseases","volume":"37","author":"Iniguez","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1172\/JCI117060","article-title":"Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids","volume":"93","author":"Crofford","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB12","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1172\/JCI117620","article-title":"Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction","volume":"94","author":"Harris","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB13","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1053\/gast.1996.v111.pm8690211","article-title":"Characterization of prostaglandin G\/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts","volume":"111","author":"Kargman","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB14","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1096\/fasebj.5.9.1907252","article-title":"Human platelet\/erythroleukemia cell prostaglandin G\/H synthase","volume":"5","author":"Funk","year":"1991","journal-title":"FASEB J"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB15","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1152\/ajprenal.2001.281.1.F1","article-title":"Physiological regulation of cyclooxygenase-2 in the kidney","volume":"281","author":"Harris","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB16","doi-asserted-by":"crossref","first-page":"6628","DOI":"10.1074\/jbc.275.9.6628","article-title":"Transforming growth factor-beta1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA","volume":"275","author":"Sheng","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB17","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","article-title":"The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase","volume":"2","author":"Loll","year":"1995","journal-title":"Nat Struct Biol"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB18","first-page":"8","article-title":"NSAID induced gastrointestinal complications","volume":"51","author":"Singh","year":"1998","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB19","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","article-title":"Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs","volume":"340","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB20","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJM200108093450607","article-title":"The coxibs, selective inhibitors of cyclooxygenase-2","volume":"345","author":"FitzGerald","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB21","first-page":"1705","article-title":"Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases","volume":"271","author":"Patrignani","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB22","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.1073\/pnas.96.13.7563","article-title":"Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity","volume":"96","author":"Warner","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB23","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","article-title":"Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis","volume":"343","author":"Bombardier","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB24","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4065\/74.11.1095","article-title":"Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor","volume":"74","author":"Bensen","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB25","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0","article-title":"Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip","volume":"43","author":"Cannon","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB26","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00003495-200059040-00017","article-title":"Celecoxib","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB27","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/archinte.160.12.1781","article-title":"A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib versus ibuprofen in patients with osteoarthritis","volume":"160","author":"Day","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","article-title":"Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, double-blind, placebo-controlled trial","volume":"43","author":"Hawkey","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB29","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1001\/jama.282.20.1921","article-title":"Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis","volume":"282","author":"Simon","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB30","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0009-9236(99)70113-X","article-title":"Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model","volume":"65","author":"Ehrich","year":"1999","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB31","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/S0149-2918(99)80045-9","article-title":"Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain","volume":"21","author":"Malmstrom","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0149-2918(99)80016-2","article-title":"Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain","volume":"21","author":"Morrison","year":"1999","journal-title":"Clin Ther"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB33","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0029-7844(99)00360-9","article-title":"Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea","volume":"94","author":"Morrison","year":"1999","journal-title":"Obstet Gynecol"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","article-title":"A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis","volume":"117","author":"Laine","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","article-title":"Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis","volume":"284","author":"Silverstein","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB36","series-title":"Briefing Information","year":"2001"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB37","series-title":"Briefing Information","year":"2001"},{"key":"10.1016\/S0002-9149(02)02231-2_BIB38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1053\/gast.2001.21907","article-title":"Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient","volume":"120","author":"Laine","year":"2001","journal-title":"Gastroenterology"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914902022312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914902022312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,1,8]],"date-time":"2020-01-08T07:02:12Z","timestamp":1578466932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914902022312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,3]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2002,3]]}},"alternative-id":["S0002914902022312"],"URL":"https:\/\/doi.org\/10.1016\/s0002-9149(02)02231-2","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2002,3]]}}}